Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company develops, validates and delivers diagnostic services that enable patient-care decisions. Its diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The Company’s MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). It also offers a range of molecular and cytogenetic testing modalities that are utilized in the management of patients with MM, such as conventional cytogenetics, molecular tests, M protein serum test and flow cytometry.